Circulating Angiogenic Factor Levels in Hypertensive Disorders of Pregnancy

BACKGROUND Among women with hypertensive disorders of pregnancy, biomarkers may stratify risk for developing preeclampsia with severe features (sPE). METHODS Across 18 U.S. centers, we prospectively measured the ratio of serum soluble fms-like tyrosine

[1]  Lorie M. Harper,et al.  Treatment for Mild Chronic Hypertension during Pregnancy. , 2022, The New England journal of medicine.

[2]  L. Magee,et al.  The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. , 2021, Pregnancy hypertension.

[3]  M. Overgaard,et al.  Decision Threshold for Kryptor sFlt-1/PlGF Ratio in Women With Suspected Preeclampsia: Retrospective Study in a Routine Clinical Setting. , 2021, Journal of the American Heart Association.

[4]  R. Kimmig,et al.  Circulating Maternal sFLT1 (Soluble fms-Like Tyrosine Kinase-1) Is Sufficient to Impair Spiral Arterial Remodeling in a Preeclampsia Mouse Model , 2021, Hypertension.

[5]  K. Nicolaides,et al.  Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes. , 2020, American journal of obstetrics and gynecology.

[6]  S. Ziebland,et al.  A core outcome set for pre‐eclampsia research: an international consensus development study , 2020, BJOG : an international journal of obstetrics and gynaecology.

[7]  B. Sibai,et al.  Placental Growth Factor and the Risk of Adverse Neonatal and Maternal Outcomes. , 2020, Obstetrics and gynecology.

[8]  J. Kuk,et al.  Changes in the prevalence of chronic conditions associated with abdominal obesity between 1999 and 2014 , 2019, Clinical obesity.

[9]  K. Joseph,et al.  Changes in the Prevalence of Chronic Hypertension in Pregnancy, United States, 1970 to 2010. , 2019, Hypertension.

[10]  Shu Yang.  Flexible Imputation of Missing Data, 2nd ed. , 2019, Journal of the American Statistical Association.

[11]  K. Tan,et al.  Short-Term Prediction of Adverse Outcomes Using the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio in Asian Women With Suspected Preeclampsia , 2019, Hypertension.

[12]  Jason D. Wright,et al.  Preeclampsia outcomes at delivery and race , 2019, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[13]  J. Hutcheon,et al.  Temporal and external validation of the fullPIERS model for the prediction of adverse maternal outcomes in women with pre-eclampsia. , 2019, Pregnancy hypertension.

[14]  M. Moore,et al.  RNAi Modulation of Placental sFLT1 for the Treatment of Preeclampsia. , 2018, Nature Biotechnology.

[15]  S. Salahuddin,et al.  Angiogenic biomarkers in triage and risk for preeclampsia with severe features. , 2018, Pregnancy hypertension.

[16]  A. Caughey,et al.  SMFM Special Report: Putting the "M" back in MFM: Reducing racial and ethnic disparities in maternal morbidity and mortality: A call to action. , 2017, American journal of obstetrics and gynecology.

[17]  B. Mol,et al.  Prediction of complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models , 2017, BMC Medicine.

[18]  S. Brennecke,et al.  Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio and Time to Delivery in Women With Suspected Preeclampsia , 2016, Obstetrics and gynecology.

[19]  S. Salahuddin,et al.  Sequential plasma angiogenic factors levels in women with suspected preeclampsia. , 2016, American journal of obstetrics and gynecology.

[20]  Christopher D. Clark,et al.  Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia. , 2016, The Journal of clinical investigation.

[21]  Johnf . Thompson,et al.  Placental Growth Factor Reduces Blood Pressure in a Uteroplacental Ischemia Model of Preeclampsia in Nonhuman Primates , 2016, Hypertension.

[22]  S. Salahuddin,et al.  KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes , 2016, Hypertension in pregnancy.

[23]  T. Benzing,et al.  Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. , 2016, Journal of the American Society of Nephrology : JASN.

[24]  S. Brennecke,et al.  Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. , 2016, The New England journal of medicine.

[25]  S. Salahuddin,et al.  Ouabain inhibits placental sFlt1 production by repressing HSP27‐dependent HIF‐1α pathway , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  N. Rioux-Leclercq,et al.  All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  C. Ananth,et al.  Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis , 2013, BMJ.

[28]  L. Mackillop,et al.  Diagnostic Accuracy of Placental Growth Factor in Women With Suspected Preeclampsia: A Prospective Multicenter Study , 2013, Circulation.

[29]  B. Sibai.  What to expect from expectant management in severe preeclampsia at <34 weeks gestation: pregnancy outcomes in developed vs developing countries. , 2013, American journal of obstetrics and gynecology.

[30]  S. Crawford,et al.  Gestational angiogenic biomarker patterns in high risk preeclampsia groups. , 2013, American journal of obstetrics and gynecology.

[31]  S. Maynard,et al.  Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia , 2012, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[32]  Stef van Buuren,et al.  Flexible Imputation of Missing Data , 2012 .

[33]  V. Sharma,et al.  Angiogenic Factors in Superimposed Preeclampsia: A Longitudinal Study of Women With Chronic Hypertension During Pregnancy , 2012, Hypertension.

[34]  K. Lim,et al.  Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia , 2012, Circulation.

[35]  C. Mueller,et al.  Heparin Strongly Induces Soluble Fms-Like Tyrosine Kinase 1 Release In Vivo and In Vitro—Brief Report , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[36]  R. Romero,et al.  Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia , 2011, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[37]  Santosh A. Khedkar,et al.  Pilot Study of Extracorporeal Removal of Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia , 2011, Circulation.

[38]  M. Ikawa,et al.  Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model , 2010, Proceedings of the National Academy of Sciences.

[39]  A. Gruber,et al.  Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model , 2009, Journal of cellular and molecular medicine.

[40]  D. Nochy,et al.  VEGF inhibition and renal thrombotic microangiopathy. , 2008, The New England journal of medicine.

[41]  N. Himes,et al.  VEGF and TGF-β are required for the maintenance of the choroid plexus and ependyma , 2008, The Journal of experimental medicine.

[42]  P. McKenzie,et al.  Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. , 2007, Kidney international.

[43]  R. Romero,et al.  Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. , 2004, American journal of obstetrics and gynecology.

[44]  K. Lim,et al.  Circulating angiogenic factors and the risk of preeclampsia. , 2004, The New England journal of medicine.

[45]  M. Klebanoff,et al.  Prediction of Adverse Outcomes by Common Definitions of Hypertension in Pregnancy , 2001, Obstetrics and gynecology.

[46]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[47]  S. Oparil,et al.  Less-tight versus tight control of hypertension in pregnancy. , 2015, The New England journal of medicine.

[48]  D. Nyholt,et al.  during pregnancy , 2022 .